Global Preimplantation Genetic Testing Market Overview
The preimplantation genetic testing market is grow USD 0.65 Billion by 2032 and is projected to register a CAGR of around 10.2% over the forecast period 2023-2032. Preimplantation genetic testing is a wide term, which is used to describe the genetic analysis of cells of an embryo, and the outcome is used for analysis and guide, which embryos should transfer to the uterus.
Also, nowadays, preimplantation genetic testing has become much more common in North America and Europe due to innovation in genetic technology like NGS and FISH over the traditional genetic technology
Population suffering from disorders related to the gene is expected to drive the preimplantation genetic testing market. Thus, awareness of people about genetic disorders helps to avoid the risk of having babies with certain genetic disorders.
March of Dimes, a voluntary health group of the US stated about 60%,34% and 6% of babies with serious birth defects were born in developing countries, middle-income countries and rich countries respectively.
Additionally,3.3 million children less than five years die each year from serious birth defects worldwide. But genetic medical services and effective interventions, especially in developing countries, could reduce disability and mortality by up to 70%.
Hence raising awareness of preimplantation genetic testing drive the global preimplantation genetic testing market.
Early diagnosis of chromosomal disorders lowers the likelihood that children would be born with inherited chromosomal abnormalities, potentially reducing the number of children with congenital illnesses. Due to the rise in demand for PGT services in recent years, this has occurred. Additionally, it is projected that the market for genomic diagnostics would have increased demand due to the rising prevalence of numerous gene-related ailments.
It is also anticipated that preimplantation genetic diagnosis (PGD), which is already advised for couples undergoing IVF therapy due to infertility and advanced maternal age, will experience significant demand, which will in turn have a positive impact on the market's growth. Preimplantation genetic testing demand is also anticipated to rise as a result of positive market participant and service provider actions to promote IVF treatments.
In July 2023, Thermo Fisher Scientific unveiled two novel PGT-A research instruments utilizing next-generation sequencing technology. This type of testing is utilized for intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF). The Ion Torrent Genexus Integrated Sequencer offers two research-use reproductive health tests: the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit. This implementation provides more research laboratories with the benefits of next-generation sequencing, allowing for efficient internal testing and analysis.
In January 2023, the domestic genetic testing business MedGenome is actively pursuing opportunities for inorganic expansion in order to extend its operations in expanding areas. The organization is currently open to strategic relationships with enterprises worldwide and offers a complete genetic diagnostic array of over 1,300 tests in India, covering the major areas of genetic applications. The company claims that their Claria suite offers the most precise non-invasive prenatal screening tests (NIPT), genetic carrier screening tests (GCST), and preimplantation genetic screening and diagnosis (PGS/PGD), which entails analyzing the genes of an unborn child. Furthermore, Claria offers cytogenetic tests that analyze chromosomes for genetic disorders, alongside conventional prenatal diagnostics (diagnosis conducted before childbirth).
In October 2022, Cooper Genomics acquired a license for BioSkryb Genomics' patented ResolveDNA genomic amplification technology in order to enhance its preimplantation genetic testing (PGT) capabilities. Thanks to the agreement, Cooper will have the opportunity to globally market and distribute BioSkryb technology for the PGT and women's reproductive health sectors. Under the deal, Cooper will gain access to BioSkryb's ResolveDNA single-cell genomic amplification technology, which utilizes the innovative Primary Template-directed Amplification (PTA) technology. Acquiring the BioSkryb technology would enhance Cooper Genomics' positive impact on the field of women's reproductive health and on patients worldwide by providing a higher degree of genetic analysis and testing precision.
Preimplantation Genetic Testing Market Segment Insights
The global preimplantation genetic testing market is segmented based on procedure, type, application, technology, product and service, end user, and region.
Preimplantation Genetic Testing Procedure Insights
The global market for preimplantation genetic testing, by procedure, is segmented into preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS).
Preimplantation Genetic Testing Type Insights
By type, it is divided into chromosomal abnormalities, X-linked diseases, embryo testing, aneuploidy screening, LA typing, and others.
Preimplantation Genetic Testing Application Insights
By Application it is segmented into embryo HLA typing for stem cell therapy prognosis, late-onset genetic disorders, inherited the genetic disease and others.
Preimplantation Genetic Testing Technology Insights
By technology, the market is divided into next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, comparative genomic hybridization, and single-nucleotide polymorphism.
Preimplantation Genetic Testing Product and Service Insights
By product and service, it is divided into reagents and consumables, instruments and software and services.
Preimplantation Genetic Testing End User Insights
Lastly by end user the market is divided into maternity centers & fertility clinics, hospitals, diagnostic labs and research laboratories & academic institutes.
Preimplantation genetic diagnosis (PGD) segment is expected to hold the largest market share of the preimplantation genetic testing market owing to rising awareness patients as well as healthcare professionals about genetic testing. Also, preimplantation genetic screening (PGS) segment is anticipated profitable growth during the forecast period as it reduces the miscarriage risk, increase the possibility of a healthy pregnancy in all age groups
By technology, the next-generation sequencing segment also expected to hold a large share as its cost is reduced and its capability to detect mosaicism.
By product & service, the reagents and consumables segment expected to hold the largest market share as there is continuous declination infertility of female due to the increase in maternity age.
Preimplantation Genetic Testing Regional Insights
In the current scope of the study, the segments mentioned above are covered into four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
The preimplantation genetic testing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Preimplantation Genetic Testing market in the Middle East and Africa has been segmented into the Middle East and Africa.
Preimplantation Genetic Testing Market Top Key Players
- Natera, Inc.
- CooperSurgical, Inc.
- Hoffmann-La Roche AG
- Illumina, Inc.
- IGENOMIX
- Reprogenetics, LLC
- Genea Limited
- PerkinElmer, Inc.
- Genesis Genetics Ltd.
- Quest Diagnostics Incorporated
- Thermo Fisher Scientific, Inc
- Bioarrayn Genetics
- Laboratory Corporation of America Holdings
- California Pacific Medical Center
- Reproductive Health Science Ltd
October 2022: To improve its preimplantation genetic testing (PGT) capabilities, Cooper Genomics has licensed BioSkryb Genomics' patented ResolveDNA genomic amplification technology. Cooper will be able to sell and distribute BioSkryb technology for the PGT and women's reproductive health markets internationally due to the deal. ResolveDNA single-cell genomic amplification technology from BioSkryb, which combines unique Primary Template-directed Amplification (PTA) technology, will be made available to Cooper as a result of the agreement. Gaining access to the BioSkryb technology would boost Cooper Genomics' beneficial effects on the field of women's reproductive health and on the lives of patients everywhere by enabling a new level of genetic analysis and testing accuracy.
Regional Market Summary
March of Dimes, the US voluntary health group stated that 7.9 million children are born with a serious birth defect of genetic or partially genetic origin, that is, 6% of total births in a year worldwide. This estimation is drawn from a study of 193 countries. As the genetic defects are growing, there is an increase in awareness about preimplantation genetic testing in population worldwide.
US Department of Health & Human Services stated that Infertility is very common. Thus, out of 100 couples in the US, about 12 to 13 of them have trouble getting pregnant. About 10 in 100 (6.1 million) women in the US aged 15 to 44 have a problem in getting pregnant or staying pregnant. Hence the prevalence of infertility causes an increase in the number of IVF procedures in the US, which is expected to drive the market.
As the maternal age in Europe is increasing complications regarding childbirth along with the threat of abnormalities in chromosomes is also rising. This leads to an increase in preimplantation genetic testing for baby birth with normal genes.
The rising participation of market players is also strongly impacting the growth of the Asia-Pacific Preimplantation Genetic Testing market.
On the other hand, the Middle East and Africa held the least share in the global market due to the low economic development, especially within the African region.
Preimplantation Genetic Testing Market Segmentation
Preimplantation Genetic Testing Procedure Outlook
- Preimplantation Genetic Diagnosis (PGD)
- Preimplantation Genetic Screening (PGS) Beta Thalassemia
Preimplantation Genetic Testing Type Outlook
- Chromosomal Abnormalities
- X-linked Diseases
- Embryo Testing
- Aneuploidy Screening
- HLA Typing
- Others
Preimplantation Genetic Testing Application outlook
- Embryo HLA typing for stem cell therapy
- IVF Prognosis
- Late-Onset Genetic Disorders
- Inherited Genetic Disease
- Others
Preimplantation Genetic Testing Technology Outlook
- Next-Generation Sequencing
- Polymerase Chain Reaction
- Fluorescence in Situ Hybridization
- Comparative Genomic Hybridization
- Single-Nucleotide Polymorphism
Preimplantation Genetic Testing Product and Service Outlook
- Reagents and Consumables
- Instruments
- Software and Services
Global Preimplantation Genetic Testing End User outlook
- Maternity Centers & Fertility Clinics
- Hospitals, Diagnostic Labs
- Research Laboratories & Academic Institutes
Global Preimplantation Genetic Testing Region Outlook
- Americas
- North America
- Latin America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Intended Audience
- Pharmaceutical companies
- Government and private laboratories
- Research and development (R&D) companies
- Research laboratories
- Market research and consulting service providers
| Report Attribute/Metric |
Details |
| Â Â Market Size |
  USD 0.65 Billion (By 2032) |
| Â Â CAGR |
  10.2% |
| Â Â Base Year |
  2022 |
| Â Â Forecast Period |
  2023-2032 |
| Â Â Historical Data |
  2021 |
| Â Â Forecast Units |
  Value (USD Billion) |
| Â Â Report Coverage |
  Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered |
  Procedure, Type, Application, Technology, Product and Service |
| Â Â Geographies Covered |
  North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors |
  Natera, Inc.CooperSurgical, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., IGENOMIX, Reprogenetics, LLC, Genea Limited, PerkinElmer, Inc., Genesis Genetics Ltd., Quest Diagnostics Incorporated, Thermo FisherScientific, Inc, Bioarrayn Genetics, Laboratory Corporation of America Holdings, California Pacific Medical Center and Reproductive Health Science Ltd |
| Â Â Key Market Opportunities |
  New product launches and R&D Amongst major key Players |
| Â Â Key Market Drivers |
  Rising awareness regarding its benefits |
Preimplantation Genetic Testing Market Highlights:
Frequently Asked Questions (FAQ) :
The preimplantation genetic testing market would register a CAGR of 10.2% during the forecast period.
The preimplantation genetic testing market valuation in 2032 USD 0.65 Billion.
Rising awareness regarding its benefits would increase the preimplantation genetic testing market volume.
The Preimplantation genetic diagnosis (PGD) segment would lead to the preimplantation genetic testing market.
The next-generation sequencing has the upper hand in the preimplantation genetic testing market.
